{"id":41951,"date":"2025-09-22T14:41:46","date_gmt":"2025-09-22T06:41:46","guid":{"rendered":"https:\/\/flcube.com\/?p=41951"},"modified":"2025-09-22T14:41:47","modified_gmt":"2025-09-22T06:41:47","slug":"pfizer-and-arvinas-pass-commercial-rights-of-vepdegestrant-to-third-party","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41951","title":{"rendered":"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) and <strong>Arvinas, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ARVN:NASDAQ\">NASDAQ: ARVN<\/a>) announced that they are stepping back from the commercialization of the estrogen\u2011receptor (ER) degrader <strong>vepdegestrant<\/strong>. The two companies will hand the primary commercial rights to a third party, a move that follows the termination of two Phase\u202fIII trials and a shift in strategic focus.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-background\">Background<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Filing<\/strong>: On September\u202f17, Pfizer and Arvinas jointly submitted a New Drug Application for vepdegestrant, an oral PROteolysis TArgeting Chimera (PROTAC).<\/li>\n\n\n\n<li><strong>Prior Development<\/strong>: The program had already scaled back earlier development plans, focusing on vepdegestrant as a second\u2011line monotherapy after the early\u2011stage trials.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-termination\">Clinical Trial Termination<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fIII End<\/strong>: In May\u202f2025, both the vepdegestrant\u202f+\u202fPfizer\u2019s investigational CDK4 inhibitor atirmociclib trial and the vepdegestrant\u202f+\u202fCDK4\/6 inhibitor trial were discontinued.<\/li>\n\n\n\n<li><strong>Regulatory Insight<\/strong>: Discussions with the FDA suggested that the most promising setting for ER\u2011targeted therapies is in second\u2011line and later lines of therapy for patients harboring ESR1 gene mutations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-shift\">Strategic Shift<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Focus on Second\u2011Line Monotherapy<\/strong>: With the NDA now targeting second\u2011line use, Pfizer and Arvinas decided to outsource commercialization to a partner better positioned to navigate the narrower indication.<\/li>\n\n\n\n<li><strong>Arvinas Pipeline Rebalancing<\/strong>: The company will re\u2011allocate resources to its early\u2011stage PROTAC degraders:<\/li>\n\n\n\n<li><strong>ARV\u2011102<\/strong> \u2013 LRRK2 degrader (Phase\u202fI)<\/li>\n\n\n\n<li><strong>ARV\u2011393<\/strong> \u2013 BCL6 degrader (Phase\u202fI)<\/li>\n\n\n\n<li><strong>ARV\u2011806<\/strong> \u2013 KRAS\u202fG12D degrader (Phase\u202fI)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investor Outlook<\/strong>: The decision may lower short\u2011term revenue expectations but frees capital for Arvinas to accelerate its next\u2011generation degraders.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Vepdegestrant\u2019s commercial future will now depend on the partner\u2019s ability to secure reimbursement and market access in a highly competitive oncology arena.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41956,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2702,16,2703,863,309,70],"class_list":["post-41951","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-arvinas","tag-cancer","tag-nasdaq-arvn","tag-nyse-pfe","tag-pfizer","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back from the commercialization of the estrogen\u2011receptor (ER) degrader vepdegestrant. The two companies will hand the primary commercial rights to a third party, a move that follows the termination of two Phase\u202fIII trials and a shift in strategic focus.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41951\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back from the commercialization of the estrogen\u2011receptor (ER) degrader vepdegestrant. The two companies will hand the primary commercial rights to a third party, a move that follows the termination of two Phase\u202fIII trials and a shift in strategic focus.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41951\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T06:41:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-22T06:41:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party\",\"datePublished\":\"2025-09-22T06:41:46+00:00\",\"dateModified\":\"2025-09-22T06:41:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2201.webp\",\"keywords\":[\"Arvinas\",\"Cancer\",\"NASDAQ: ARVN\",\"NYSE: PFE\",\"Pfizer\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41951#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41951\",\"name\":\"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2201.webp\",\"datePublished\":\"2025-09-22T06:41:46+00:00\",\"dateModified\":\"2025-09-22T06:41:47+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back from the commercialization of the estrogen\u2011receptor (ER) degrader vepdegestrant. The two companies will hand the primary commercial rights to a third party, a move that follows the termination of two Phase\u202fIII trials and a shift in strategic focus.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41951\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41951#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back from the commercialization of the estrogen\u2011receptor (ER) degrader vepdegestrant. The two companies will hand the primary commercial rights to a third party, a move that follows the termination of two Phase\u202fIII trials and a shift in strategic focus.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41951","og_locale":"en_US","og_type":"article","og_title":"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party","og_description":"Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back from the commercialization of the estrogen\u2011receptor (ER) degrader vepdegestrant. The two companies will hand the primary commercial rights to a third party, a move that follows the termination of two Phase\u202fIII trials and a shift in strategic focus.","og_url":"https:\/\/flcube.com\/?p=41951","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-22T06:41:46+00:00","article_modified_time":"2025-09-22T06:41:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41951#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41951"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party","datePublished":"2025-09-22T06:41:46+00:00","dateModified":"2025-09-22T06:41:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41951"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41951#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2201.webp","keywords":["Arvinas","Cancer","NASDAQ: ARVN","NYSE: PFE","Pfizer","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41951#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41951","url":"https:\/\/flcube.com\/?p=41951","name":"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41951#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41951#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2201.webp","datePublished":"2025-09-22T06:41:46+00:00","dateModified":"2025-09-22T06:41:47+00:00","description":"Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back from the commercialization of the estrogen\u2011receptor (ER) degrader vepdegestrant. The two companies will hand the primary commercial rights to a third party, a move that follows the termination of two Phase\u202fIII trials and a shift in strategic focus.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41951#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41951"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41951#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2201.webp","width":1080,"height":608,"caption":"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41951#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41951"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41951\/revisions"}],"predecessor-version":[{"id":41957,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41951\/revisions\/41957"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41956"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}